Breast Cancer, Peripheral Neuropathy, Gynecologic Cancer
Conditions
Keywords
breast cancer, neuropathy, peripheral neuropathy, yoga, 17-449
Brief summary
Some types of chemotherapy used to treat breast cancer can cause damage to nerves with symptoms like tingling, numbness, muscle weakness, and pain in the hands and feet that can last and can affect functioning. The purpose of this study is to find out the effects of yoga on reducing symptoms caused by such nerve damage.
Interventions
OTHERYoga
Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
OTHERWait List Control
Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* English-speaking * Age \>/= 18 years old * Survivors with a primary diagnosis of stage I-III breast, ovarian uterine, or endometrial cancer * Moderate to severe chemotherapy induced peripheral neuropathy, defined by symptoms such as numbness, tingling, or pain ratings of 4 or greater on a 0-10 numeric rating scale * Have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment * If taking anti-neuropathy medications, they are on a stable regiment (no change in 3 months) * ECOG performance status 0-2
Exclusion criteria
* Participants with metastatic disease * Participants who are currently receiving physical therapy or practicing yoga for any reason Control Group - Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in treatment related peripheral neuropathy symptoms | 8 weeks of the participants' most bothersome peripheral neuropathy symptom | Treatment related symptoms will be evaluated by using NCI CTCAE v4.0 |
Countries
United States
Outcome results
None listed